Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review
Sign Up to like & getrecommendations! Published in 2019 at "Rheumatology International"
DOI: 10.1007/s00296-019-04268-x
Abstract: Tocilizumab (TCZ) may rarely cause hematological side effects including neutropenia and thrombocytopenia. TCZ is essentially expected to lower the fibrinogen levels to stay within the normal range, but TCZ-induced hypofibrinogenemia has been rarely reported in… read more here.
Keywords: fibrinogen; tcz; routinely check; review ... See more keywords
Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology International"
DOI: 10.1007/s00296-020-04596-3
Abstract: Introduction Juvenile idiopathic arthritis (JIA) is a heterogeneous group of idiopathic inflammatory arthritis affecting children younger than 16 years of age. Tocilizumab (TCZ) is a humanized anti-interleukin 6 (IL-6) receptor antibody that was approved for systemic… read more here.
Keywords: satisfaction; juvenile idiopathic; tcz; study ... See more keywords
Use of tocilizumab in systemic sclerosis: A brief literature review.
Sign Up to like & getrecommendations! Published in 2018 at "Revista Clinica Espanola"
DOI: 10.1016/j.rceng.2018.02.010
Abstract: Abstract The available treatments for systemic sclerosis (SS) have limited effectiveness. Treatment with tocilizumab (TCZ), a biological drug that inhibits interleukin 6 (IL-6), has recently been proposed. In this study, we conducted a literature review… read more here.
Keywords: systemic sclerosis; tcz; literature review;
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
Sign Up to like & getrecommendations! Published in 2019 at "Seminars in arthritis and rheumatism"
DOI: 10.1016/j.semarthrit.2019.01.003
Abstract: OBJECTIVE Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected patients with GCA in clinical… read more here.
Keywords: giant cell; observational open; clinical practice; tcz ... See more keywords
Assessment of pancreatitis associated with tocilizumab use using the United States Food and Drug Administration Adverse Event Reporting System database
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-98325-w
Abstract: Tocilizumab (TCZ) is used to treat rheumatoid arthritis and other systemic inflammatory disorders. There is some evidence suggesting the occurrence of pancreatitis following TCZ use. We aimed to determine the reporting of pancreatitis following TCZ… read more here.
Keywords: reporting; pancreatitis; adverse event; use ... See more keywords
Formulation and in vivo assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery
Sign Up to like & getrecommendations! Published in 2018 at "Drug Delivery"
DOI: 10.1080/10717544.2018.1436098
Abstract: Abstract The aim of the current study was to formulate terconazole (TCZ) loaded polymeric mixed micelles (PMMs) incorporating Cremophor EL as a stabilizer and a penetration enhancer. A 23 full factorial design was performed using… read more here.
Keywords: optimal pmms; pmms; delivery; tcz ... See more keywords
Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy
Sign Up to like & getrecommendations! Published in 2019 at "Modern Rheumatology"
DOI: 10.1080/14397595.2018.1452178
Abstract: Abstract Objectives: To evaluate the anti-interleukin (IL)-6 receptor antibody tocilizumab (TCZ) as a treatment of systemic sclerosis (SSc), a randomised parallel group study was conducted, and compared their results and baseline cytokine/chemokine profiles. Methods: Patients… read more here.
Keywords: tcz; group; systemic sclerosis; therapy ... See more keywords
The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients
Sign Up to like & getrecommendations! Published in 2020 at "Modern Rheumatology"
DOI: 10.1080/14397595.2019.1709258
Abstract: Abstract Aim Interleukin-6 receptor antagonist, tocilizumab (TCZ), is known to be effective in the treatment of amyloidosis in patients with familial Mediterranean fever (FMF). But there are limited data about the effect of TCZ on… read more here.
Keywords: frequency; tcz; patients familial; study ... See more keywords
Effective Therapy of Tocilizumab on Systemic Juvenile Idiopathic Arthritis Associated Refractory Macrophage Activation Syndrome.
Sign Up to like & getrecommendations! Published in 2021 at "Modern rheumatology"
DOI: 10.1093/mr/roab119
Abstract: OBJECTIVES To evaluate the safety and efficacy of tocilizumab (TCZ) on refractory macrophage activation syndrome (rMAS) associated with systemic juvenile idiopathic arthritis (sJIA-rMAS). METHODS We retrospectively reviewed the charts of 14 patients diagnosed with sJIA-rMAS,… read more here.
Keywords: arthritis; tcz; macrophage activation; refractory macrophage ... See more keywords
Effectiveness of Combination Tocilizumab and Glucocorticoids as an Induction Therapy in Patients with Takayasu Arteritis: An Observational Study.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac033
Abstract: BACKGROUND The efficacy of tocilizumab (TCZ) in the treatment of Takayasu arteritis (TA) was demonstrated in randomized controlled trials. The objective of this study was to analyze the effectiveness of combining TCZ with glucocorticoids (GC)… read more here.
Keywords: induction therapy; tcz; combination; study ... See more keywords
#3105 Tocilizumab for treatment of antibody mediated rejection in kidney transplant patients
Sign Up to like & getrecommendations! Published in 2024 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfae069.1694
Abstract: Chronic active antibody-mediated rejection (caABMR) causes 40% of long-term graft failure after kidney transplantation (KT). Early treatment is of great importance, however, hard clinical evidence is still lacking. Currently the combination of plasmapheresis (PF), rituximab… read more here.
Keywords: antibody mediated; treatment; therapy; antibody ... See more keywords